Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market
Number of pages: 100 | Report Format: PDF | Published date: April 27, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 12.71 billion |
|
Revenue Forecast in 2031 |
US$ 20.95 billion |
|
CAGR |
6.45% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Disease Type, Drug Therapy, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global focal segmental glomerulosclerosis (FSGS) therapeutics market was valued at US$ 12.71 billion in 2022 and is expected to register a revenue CAGR of 6.45% to reach US$ 20.95 billion by 2031.
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market Fundamentals
Focal segmental glomerulosclerosis (FSGS) is an uncommon, chronic kidney disease marked by scarring and destruction to the glomeruli, the small filters in the kidneys that help eliminate waste and excess fluid from the circulation. Proteinuria (excess protein in the urine), nephrotic syndrome (a collection of symptoms that includes proteinuria, hypoalbuminemia, edema, and high cholesterol), and progressive loss of kidney function can all result in end-stage renal disease (ESRD) requiring dialysis or kidney transplantation.
There are various potential trends and prospects in the field of FSGS treatments, including precision medicine, innovative therapeutic targets, immune modulation, combination therapy, patient-centric methods, and current clinical studies. These developments could enhance FSGS management, provide more effective therapies, and, eventually, improve patient outcomes. However, further research and clinical trials are needed to fully understand the safety and effectiveness of these developing medicines and their long-term effects on FSGS patients.
Players in the FSGS therapeutics market use various methods to boost their earnings, including R&D, partnerships, pricing & reimbursement strategies, marketing & promotion, patient support programs, and post-marketing surveillance. These tactics attempt to speed up product development, broaden market presence, improve patient access, and enhance demand for FSGS treatments. Additionally, some players are investing in technological advancements such as precision medicine and gene therapy to improve the efficacy of FSGS treatments. These strategies are expected to drive the growth of the FSGS therapeutics market in the coming years.
[123]
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market Dynamics
The global prevalence of focal segmental glomerulosclerosis (FSGS) is increasing due to various risk factors, including obesity, diabetes, and hypertension. For instance, According to Neph Cure's 2023 projections, approximately 40,000 people in the United States have FSGS, and more than 5,400 are diagnosed yearly. The expanding patient population with FSGS necessitates the development of novel and effective therapies, fueling market revenue growth.
However, ongoing research into the underlying mechanisms of FSGS provides insights for developing more targeted and effective treatments in the forecast years. One promising avenue of research is focused on the role of certain immune cells in developing FSGS, which could lead to the development of immunomodulatory therapies. Additionally, genetic testing and personalized medicine advances may lead to more modified treatment options for individuals with FSGS. Significant progress has been made in understanding the pathophysiology of FSGS, which has resulted in the identification of novel treatment targets and medication candidates. Research and development advances, such as utilizing targeted treatments, immunosuppressive drugs, and other novel treatment methods, propel the FSGS therapeutics market. These developments provide promising therapy choices and the possibility for improved patient outcomes, which will enhance demand for FSGS medicines.
Despite the growing prevalence of FSGS, the lack of effective treatment options and the high cost of existing therapies are major restraining factors for the FSGS therapeutics market. Additionally, the limited understanding of disease pathogenesis and heterogeneity further complicates drug development efforts.
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market Ecosystem
The global focal segmental glomerulosclerosis (FSGS) therapeutics market is analyzed from the following perspectives: disease type, drug therapy, and region.
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market by Disease Type
[145]
Based on disease type, the global focal segmental glomerulosclerosis (FSGS) therapeutics market is segmented into primary FSGS and secondary FSGS.
The primary FSGS segment has dominated the global focal segmental glomerulosclerosis (FSGS) therapeutics market, with a high revenue share in 2022. This dominance of the primary FSGS segment is attributed to the increasing prevalence of primary FSGS. According to Kidney International, the frequency of primary FSGS has increased twice to thrice in the last 20 years, partly due to the inclusion of a spectrum of glomerular lesions or "variants" under the diagnosis of main FSGS.
The secondary FSGS segment is expected to show high revenue growth in the global focal segmental glomerulosclerosis (FSGS) therapeutics market. This growth can be attributed to the increased prevalence of secondary FSGS among adults and children and the rising demand for effective treatment options in secondary focal segmental glomerulosclerosis. Moreover, research and development in the field of nephrology have led to the discovery of new drugs and therapies that can effectively manage the symptoms of secondary FSGS, further contributing to the market’s growth.
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market by Drug Therapy
Based on drug therapy, the global focal segmental glomerulosclerosis (FSGS) therapeutics market is segmented into angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), immunosuppressants, diuretics, and corticosteroids.
In 2022, the immunosuppressants held the majority of the global focal segmental glomerulosclerosis (FSGS) therapeutics market revenue share. Immunosuppressants have been shown to be effective in treating FSGS by reducing inflammation and preventing further kidney damage. Moreover, immunosuppressants stabilize the lysosomal membranes and inhibit lymphocyte and antibody formation. Furthermore, these drugs are also used to prevent the rejection of transplanted organs.
Corticosteroids are often used as the first-line treatment for FSGS, as they have been shown to improve kidney function and reduce proteinuria in many patients. However, some patients may not respond to corticosteroid therapy, and additional treatments, such as immunosuppressive drugs or plasma exchange, may be necessary.
ACEIs have been shown to reduce proteinuria and slow the progression of renal disease in patients with FSGS, but their effectiveness may vary depending on the underlying cause of FSGS. Additional studies are needed to determine the optimal dosing and duration of ACEI therapy in this patient population. ARBs have been found to be effective in reducing proteinuria and preserving renal function in patients with FSGS. However, their use should be carefully monitored as they may cause hyperkalemia and hypotension in some patients.
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market by Region
Based on the region, the global focal segmental glomerulosclerosis (FSGS) therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounted for the highest revenue share in 2022. The increasing prevalence of chronic kidney diseases and the growing demand for advanced treatment options are the major factors driving North America's growth of the FSGS therapeutics market. Additionally, the presence of key market players and favorable government initiatives to increase awareness contribute to North America's market growth. Moreover, advanced healthcare infrastructure, adoption of advanced therapies, and rising investment in R&D activities are expected to boost the market’s growth during the forecast period.
The European focal segmental glomerulosclerosis (FSGS) therapeutics market is characterized by the presence of several key players operating in the region, including major pharmaceutical companies and biotech firms. These companies invest heavily in research and development activities to introduce innovative treatment options for FSGS patients. Furthermore, the increasing prevalence of FSGS in Europe drives the demand for effective therapeutics. The growing healthcare infrastructure and favorable government initiatives are expected further to boost the market growth in the forecast years.
The Asia Pacific focal segmental glomerulosclerosis (FSGS) therapeutics market is expected to grow significantly in the forecast years due to the increasing prevalence of kidney diseases and the rising demand for effective treatment options. Additionally, advancements in medical technology and growing healthcare expenditure are expected to contribute to the market growth. Countries such as India and China in the APAC region are projected to offer significant growth opportunities owing to the growing population, rising incidence of chronic diseases, and booming pharmaceutical industry in the region.
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market Competitive Landscape
The focal segmental glomerulosclerosis (FSGS) therapeutics market is highly competitive, with major players such as Retrophin Inc., AbbVie Inc., and Pfizer Inc. dominating the market. The market is expected to grow significantly due to the increasing prevalence of FSGS and the growing demand for effective treatment options. Moreover, the rise in research and development activities for developing novel therapeutics is also expected to contribute to the growth of the FSGS therapeutics market. However, high treatment costs and a lack of awareness about the disease in developing countries may hinder market growth.
Some of the prominent companies having the largest revenue share in the global focal segmental glomerulosclerosis (FSGS) therapeutics market are,
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market Recent Developments
The focal segmental glomerulosclerosis (FSGS) therapeutics market is expected to grow significantly due to the increasing prevalence of FSGS and the rising demand for effective treatment options. The development of novel therapies and personalized medicine is also expected to drive market growth in the coming years.
According to the deep-dive market assessment study by Growth Plus Reports, the global focal segmental glomerulosclerosis (FSGS) therapeutics market was valued at US$ 12.71 billion in 2022.
Some major strategies key market players adopt in the focal segmental glomerulosclerosis (FSGS) therapeutics market include mergers and acquisitions, collaborations, partnerships, and product launches. These strategies help companies to expand their market presence and strengthen their position in the competitive landscape.
Based on disease type, the global focal segmental glomerulosclerosis (FSGS) therapeutics market is segmented into primary FSGS and secondary FSGS. The primary FSGS segment has dominated the global focal segmental glomerulosclerosis (FSGS) therapeutics market, with a high revenue share in 2022.
The global focal segmental glomerulosclerosis (FSGS) therapeutics market was valued at US$ 12.71 billion in 2022 and is expected to register a revenue CAGR of 6.45% to reach US$ 20.95 billion by 2031.
*Insights on financial performance are subject to the availability of information in the public domain